Cybersecurity Startups Raised $6.8 Billion in Q3 2026 on Fewer Deals, With Three Rounds Taking $1.8 Billion

Global cybersecurity and privacy startups raised $6.8 billion in the third quarter of 2026, about 50% more than in the prior quarter and tied for the highest quarterly total in years, Crunchbase News reported on October 15. The article's author, Joanna Glasner, wrote that round counts fell sequentially at every stage.

More money across fewer rounds means the total is a story about a handful of cheques. Our earlier coverage of Modal's $750 million Series D is a single-cheque story of the same kind. Three of them account for $1.8 billion, about 26% of the quarter by this arithmetic, which Crunchbase does not itself state.

The three rounds that make the quarter

Keyfactor, the Ohio company founded in 2001, raised a $1 billion growth round in July led by Summit Partners. Island, in Dallas, raised a $400 million Series F in September led by Evolution Equity Partners at a $6.4 billion post-money valuation. Cyera, in New York, raised $400 million in September led by Goldman Sachs Growth Equity at a $12 billion valuation, three months after a $600 million raise.

1. Keyfactor (July)1000 $ million
2. Island (September)400 $ million
3. Cyera (September)400 $ million

Source: Crunchbase News, October 15, 2026

Cyera has therefore taken $1 billion in three months. At $12 billion post-money, that is a company priced on the expectation that its next round is larger than this one. Cyera also bought Oasis Security, reportedly valued at about $1 billion.

At least 18 companies at the intersection of AI and security closed rounds of $100 million or more, Crunchbase said. That is a count of large rounds sitting inside a quarter in which total round counts fell, and the article does not say which stages lost deals to the large ones.

Company	Round	Lead	Valuation
Keyfactor	$1 billion growth, July	Summit Partners	not given
Island	$400 million Series F, September	Evolution Equity Partners	$6.4 billion post-money
Cyera	$400 million growth, September	Goldman Sachs Growth Equity	$12 billion

The counter-case

One reading is that nothing structural changed: a quarter with a $1 billion round in it will always look strong, and three cheques can move a total by a quarter. Crunchbase's own framing, that the increase came from larger rounds and not more deals, is consistent with that. On this reading, the 50% is an artefact of lumpy late-stage deals.

The other reading is that the money is concentrating on purpose. Cyera drew $600 million and then $400 million within three months at a $12 billion valuation, which looks less like a one-off and more like a company raising whenever a lead will write the cheque. Investors writing fewer, bigger cheques would produce exactly the pattern Crunchbase counts. The data in the article cannot separate these, because it gives no stage-by-stage totals.

What would settle it is a quarter without a $1 billion round. If Q4 totals stay near $6.8 billion with Keyfactor-sized deals absent, concentration is real and spreading. If they fall back toward the prior quarter's level, which is about $4.5 billion by Crunchbase's 50% figure, the third quarter was lumpy. That $4.5 billion is derived from the rounded percentage, not a number Crunchbase prints.

The exits

Visa agreed on August 3 to buy the Israeli fraud-detection company BioCatch for $2.4 billion in cash, Globes reported. It was the largest M&A deal of the quarter in Crunchbase's count.

Permira had taken control at a $1.3 billion valuation, buying $750 million of shares from Bain Capital and Maverick Ventures to reach 57%. The Visa price is 1.8 times that entry figure, a gap worth setting beside Stryker's $400 million CMR Surgical investment as another large strategic cheque. Globes dates the Permira deal to "last March" and also describes the gain as made in 15 months, and the two do not line up, so the holding period is uncertain.

Deal	Date	Price	Acquirer
BioCatch	August 3	$2.4 billion cash	Visa
Oasis Security	Q3 2026	about $1 billion (reported)	Cyera
Qoria	July	not given	Aura

BioCatch claimed annual recurring revenue above $100 million at the end of 2023, and Globes reports 43% ARR growth in 2025 with no 2025 dollar figure. Gadi Mazor, its chief executive, said the company is not going away and that management stays. With ARR figures that are the company's own and undated beyond 2023, an exact revenue multiple cannot be calculated.

Aura completed its purchase of Australian-listed Qoria in July and renamed the combined business Aura. Crunchbase calls it the quarter's only sizeable venture-backed IPO route.

What the numbers do not show

Crunchbase's piece carries no table of the top ten recipients and its chart is not reproduced in the text, so the prior-quarter and year-ago dollar figures behind "50%" are not available here. The claim that large rounds drove the increase rests on the round-count decline and the three named cheques.

If the concentration holds, Q4 totals will depend on whether another $400 million round lands. Crunchbase's Q4 tally, due after the quarter closes on December 31, is the first data that can say.